
Vaccini stabulogeni in acquacultura: attualità e prospettive future







SIPI - Verona - 10 Novembre 2023




Total aquacolture production in tonnes



Aquacolture: Global contribution of aquaculture to gross domestic product (GDP) by country



Why aquaculture?



Aquaculture - Feed Conversion Ratio (FCR), Water Consumtion and Carbon Footprint

Farmed salmon is one of the most eco-efficient and sustainable forms of protein

	>	¥	The same of the sa	
Feed Conversion Ratio ¹	1.2-1.5*	1.7-2	2.7-5	6-10
Water Consumption ² (liter / kg edible meat)	2,000**	4,300	6,000	15,400
Carbon Footprint ¹ (grams CO ₂ -equivalent / typical serving of 40 g edible protein)	0.6*	0.9	1.3	5.9

Global Salmon Initiative (GSI) Sustainability Report. Available at: https://globalsalmoninitiative.org/en/sustainability-report/. Last accessed October 2019.

Mowi. Salmon Farming Industry Handbook 2019. Available at: http://hugin.info/209/R/2246047/887370.pdf. Last accessed October 2019.

^{*} Figures reflect feed conversion ratio and carbon footprint of farmed Atlantic salmon.


^{**} Total water footprint for farmed salmon fillets in Scotland, in relation to weight and content of calories, protein and fat.

PRESENT

PAST

FUTURE

WORLD AQUACULTURE PRODUCTION OF AQUATIC ANIMALS AND ALGAE, 1990-2018



SUPPLY CHAIN




















Aquacolture Vaccines Market - Growth Rate by



AQUACULTURE VACCINES MARKET





CAGR (2021-27): 4.4% 2020: >\$200 MN

2027: >\$265 MN

Market Value (2020):

Inactivated vaccines segment

\$163.1 MN

Trout segment

\$39.8 MN

Viral infection segment

\$31.9 MN

Regional Analysis

1 NA

CAGR (2021-27): 4.7% 2 EUROPE


Market Share (2027): >47%



Major Players

Market Concentration

- Merck & Co. Inc. (Intervet International B.V.)
- 2 Pfizer Inc. (PharmaQ)
- 3 Hipra
- 4 Tecnovax
- 5 lctyogroup





Source: Mordor Intelligence



Global Commercial Aquaculture Vaccines Market Share (%) CAGR By Region By Vaccine Type 6.7% (2020 - 2030)DNA Subunit 42.0% Attenuated Inactivated **■** Europe Latin America South Asia North America East Asia **MEA** Oceania


Asia Pacific Aquaculture Vaccines Market, 2021 & 2027 (USD Mn)





Global Veterinary Vaccines Market Analysis, 2022-2026





Vaccine types... but how many there are?

- **Live attenuated**
- Inactivated
- Sub-unitary
- Toxoid
- **■** From edible plants
 - Live attenuated virus vaccines


 Weakened SARS-CoV-2 Live attenuated virus vaccines contain functioning copies of the virus that have been weakened.


 The virus does not cause disease, but it can still replicate inside the body and induce an immune response.


 Immune response and memory

 I cell Antigen

- Conjugate
- Marker
- Deleted
- DNA/RNA
- Vector

















VACCINES AND VACCINATION STRATEGY





PREVENTION IS BETTER THAN CURE







https://doi.org/10.1111/raq.12518


II.ZZ.SS. - ITALY

- 1. DIAGNOSIS
- 2. PREVENTION
 - a. BIOSAFETY
 - b. VACCINATION STRATEGIES
 - c. RESEARCH AND DEVELOPMENT OF NEW VACCINES
 - d. PRODUCTION AND CONTROL OF AUTOGENOUS VACCINES

Pharmaceutical

Laboratory

- 3. SURVEILLANCE and CONTROL
- 4. MONITORING
- 5. COLLABORATION and COOPERATION








Autogenous Vaccine for Aquaculture Market

By Fish Species-Global value Share Analysis 2020 & 2030









Production

Authorized only in the Experimental Zooprophylactic Institutes laboratories (pharmaceutical laboratories) after permission of the Ministry of Health and under control of ISS

Protocols

Operational guidelines agreed to harmonize and standardize the production of autogenos and autologus vaccines in the IZS laboratories







The autogenous vaccine is a veterinary immunological drug prepared with pathogens and/or antigens isolated from subjects affected by infectious form (dominant in a particular farm) and used for the treatment of the same farm animals or the animals of the same "country" if the DVM believe it appropriate for evident epidemiological reasons.

How is the autogenous vaccine produced? 37 °C/24 hrs 37 °C/24 hrs phenol/formaldehyde 37 °C/72 hrs adjustment of MacFarland QS; sterility/toxicity control application ____ killed but still intact **Inactivation (growth media)** micro-organisms are Sterility (growth media) in the autovaccine Toxicity (LAL Test and/or lab. animals) DELL'UMBRIA E DELLE MARCHE "TOGO ROSATI" Formaldehyde % (residual/free)



































Regulatory Affairs...



aw

Operational guidelines agreed to harmonize and standardize the production of autogenous and autologous vaccines in the IZS laboratories...but in a short time...






- Definition
- Request
- Protocols
- Production
- Distribution




London, 20 March 2017 EMA/CMDv/452656/2016 REC-002-01

Recommendations for the manufacture, control and use of inactivated autogenous veterinary vaccines within the EEA











Quality Assurance and Quality Control

QA

 Is defined as the sum total of organized arrangements made with the objective of ensuring that the products are of quality required for their intended use.

QC

 It is the part of GMP which is concerned with sampling, specifications, testing, documentation and release which ensures that necessary and relevant tests are carried out and that materials/products are released For use/ sale only after their quality is judged to be satisfactory.

QC (Quality Control)

Meeting established Quality criteria

QA (Quality Assurance)

Confidence that Quality requirement are being met

QM (Quality Management)

Coordinated customer focused management activity including continious improvement







Premises



Equipment



Training



Personal hygiene









2-10 L 50 L 200L


















VACCINOLOGY, NEW VACCINES, GMP and COSTS







g.severi@izsum.it



+39 075.3433063







Grazie del tempo che ci siamo